11 results about "Non metastatic" patented technology

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

The invention relates to the technical field of laboratory medicine, in particular to application of IGSF3 as a serum marker in preparation of medicines for breast cancer diagnosis. The invention discovers that the expression level of serum IGSF3 in a metastatic breast cancer patient is obviously increased for the first time. The IGSF3 can be used as a serum marker for diagnosing breast cancer metastasis, the expression level of the serum IGSF3 in a metastatic breast cancer patient is remarkably improved compared with a healthy control person and a non-metastatic breast cancer patient, and ROC curve analysis shows that AUC is 0.799. The non-invasive auxiliary diagnosis of the metastatic breast cancer is carried out by using a small amount of serum samples, so that large-scale breast cancer screening is facilitated, and early discovery, early intervention and early treatment of the breast cancer are facilitated.

The present invention relates to a method based on miRNA biomarkers and clinical data for risk stratification of non-metastatic breast cancer of any molecular subtype according to the risk of developing remote metastasis, preferably in a fresh frozen sample or formalin-immobilized paraffin embedded (FFPE) sample, or in a liquid biopsy sample (serum or plasma sample). More particularly, the present invention relates to the use of 2-miRNA profiles in a prognostic model comprising two miRNAs and biomarkers that have been applied to clinical management of breast cancer patients.

Disclosed herein are antibody-drug conjugates (ADCs) comprising antibodies conjugated to an oxazaphosphine drug moiety via a linker, and methods of using the antibody drug conjugates. Including methods of treating undesirable or abnormal cell proliferative or hyperproliferative disorders, such as non-metastatic and metastatic neoplasia, cancers, stem cells, and malignancies expressing targets that bind to such antibodies or antibody fragments, antibody heavy and light chains, or nanoantibodies.

The application provides a set of biomarkers for predicting the benefit of nasopharyngeal carcinoma immunotherapy and application thereof, transcriptome data analysis of non-metastatic initial treatment of locally advanced nasopharyngeal carcinoma patients obtains a three-classification model using 318 genes as features based on nearest shrinkage centroid classification method, in the model, the event-free survival rate of patients of type 1 is significantly improved after receiving anti-PD-1 immunotherapy compared with the standard treatment group, the model can reflect the biological heterogeneity of nasopharyngeal carcinoma patients, can more accurately predict the immunotherapy benefit of nasopharyngeal carcinoma patients, and better guide clinical medication. The method for predicting the benefit of nasopharyngeal carcinoma immunotherapy can detect paraffin tissue samples, and does not depend on large sample quantity clustering, can type patients at a single sample level, has high feasibility and is easy to popularize, and has important significance for nasopharyngeal carcinoma immunotherapy.

The invention provides a group of biomarkers for predicting nasopharyngeal carcinoma immunotherapy benefit and application thereof, transcriptome data of a non-metastatic primary treatment local advanced nasopharyngeal carcinoma patient is analyzed to obtain a three-classification model which uses 318 genes as characteristics and is based on a recent systolic centroid classification method; compared with a standard treatment group, the event-free survival rate of a type 1 patient subjected to anti-PD-1 immunotherapy in the model is remarkably improved, the model can reflect the biological heterogeneity of the nasopharyngeal carcinoma patient, the immunotherapy benefit condition of the nasopharyngeal carcinoma patient can be more accurately predicted, and clinical medication can be better guided. According to the method for predicting nasopharynx cancer immunotherapy benefit, paraffin tissue sample detection can be utilized, large sample quantity clustering is not depended on, a patient can be subjected to typing at a single sample level, feasibility is high, popularization is easy, and the method has important significance on nasopharynx cancer immunotherapy.

The invention relates to a compound as shown in a formula I or salt or solvate thereof, a preparation method of the compound as shown in the formula I or a pharmaceutical composition and application thereof. The compound shown in the formula I can be used for preparing a medicine for treating a non-metastatic castration-resistant prostate cancer adult patient with a high metastasis risk, and has the advantages of being long-acting and low in toxicity.

The invention discloses a metastatic lymph node high-specificity fluorescent tracer and a preparation method and application thereof, and belongs to the field of biotechnology and medicine. The tracer takes ZIF-8 nanoparticles as a carrier, encapsulates indocyanine green (ICG), is modified by polyethylene glycol (PEG), and then is inserted into a vascular endothelial growth factor C (VEGFC) antibody to form an ICG (ZIF) PEG-VEGFC (ZIPV) compound. The particle size of the tracer is controllable (30-150 nm), the tracer emits light in a near-infrared I region (the emission wavelength is 825 nm), metastatic lymph nodes highly expressed by VEGFC can be specifically targeted, and the imaging sensitivity and specificity are remarkably improved. In-vivo and in-vitro experiments show that the ZIPV has good biocompatibility (the hemolysis rate is less than 5%), can accurately distinguish metastatic and non-metastatic lymph nodes, and has no liver and kidney toxicity. The preparation process is simple, the cost is low, and a novel tool is provided for diagnosis of gastric cancer lymph node metastasis.

The invention discloses an FELDI nano-particle chip kit and application thereof in screening metabolic marker combinations, and relates to the technical field of biology. The FELDI nano-particle chip kit comprises a methanol solution and a microarray chip which is pre-coated with iron nano-particles, the kit is used for dewaxing tissue slices, the tissue slices are immersed in a methanol solution and incubated to obtain a sample, and the sample is applied to a microarray chip pre-coated with iron nanoparticles; a colorectal cancer tissue metabolism fingerprint database is constructed, and specific metabolism markers combined with L-cysteine, adipic acid, decanoic acid, azelaic acid, pentadecanoic acid, stearic acid and isolithocholic acid are screened. The invention develops an unmarked iron nanoparticle enhanced laser desorption ionization mass spectrometry technology platform, and the small molecule metabolites can be directly and efficiently captured and ionized from the formalin-fixed paraffin-embedded CRC primary tissue section. And screening out a specific small molecule metabolism marker combination for distinguishing lymphatic metastasis and non-metastasis.